Table 1 Summary of major trials with immunotherapy in advanced cutaneous melanoma
From: Spotlight on landmark oncology trials: the latest evidence and novel trial designs
Study | N (% 1st line) | ORR | Median PFS | 2-year OS rate |
|---|---|---|---|---|
Pembrolizumab (10 mg/kg every 2 weeks) KEYNOTE-006 Robert et al., 2015 [11] Schachter et al., 2016 [12] | 279 (65.6%) | 33.7% | 5.6 months | 55.0% |
Pembrolizumab (10 mg/kg every 3 weeks) KEYNOTE-006 Robert et al., 2015 [11] Schachter et al., 2016 [12] | 277 (66.8%) | 32.9% | 4.1 months | 55.0% |
Nivolumab in BRAF-negative melanoma Checkmate-066 Robert et al., 2015 [13] | 210 (100%) | 40.0% | 5.4 months | 57.7% |
Ipilimumab + Nivolumab Checkmate-067 Larkin et al., 2015 [14] Larkin et al., 2017 [15] | 314 (100%) | 58.9% | 11.7 months | 64.0% |